newsfilter
← Latest News
GlobeNewswire·

PMV Pharmaceuticals Announces a Clinical Trial Collaboration with Merck to Evaluate PC14586 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors

CRANBURY, N.J., July 18, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (NASDAQ:PMVP, "PMV Pharma"))), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced